The newly defined AML with mutated TP53, includes cases with single (or multiple) somatic TP53 mutation with a variant allele frequency of ≥10% and ≥20% peripheral blood or bone marrow myeloid blasts/blast equivalents, or cases which meet criteria for pure erythroid leukemia. Here, TP53 is linked to acute myeloid leukemia.